The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
(MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 when administered in East Asian
participants with NHL who do not have an effective standard treatment available and to
characterize the plasma and urine pharmacokinetic (PK) of TAK-659 in East Asian participants
The drug being tested in this study is called TAK-659. TAK-659 is being tested to treat
people who have NHL or people who have relapsed and/or refractory NHL. This study will assess
the safety, tolerability, PK, and preliminary efficacy of single-agent TAK-659 in East Asian
participants with NHL.
The study will enroll approximately 33 to 47 participants, including at least 6 Japanese at
RP2D dose level. Participants will be assigned to one of the following treatment groups:
Dose Escalation Part: TAK-659 Expansion Part: TAK-659 RP2D
This multi-center trial will be conducted in Japan and Republic of Korea. The maximum
duration of participation in dose escalation part of the study is up to 12 months, unless in
the opinion of the investigator and sponsor the participant would derive benefit from
continued therapy beyond 12 months. In expansion part, participants who stop treatment for
any other reason other than PD will continue to have PFS follow-up at the site every 2 months
from the last dose of study drug up to 6 months or until PD. Participants will be followed 28
days after last dose of study drug or until the start of subsequent antineoplastic therapy,
whichever occurs first, for a follow up assessment.
1. To be enrolled to the dose escalation part, participants must have histologically or
cytologically confirmed diagnosis of NHL for which no effective standard treatment is
2. To be enrolled in the expansion part, participants must meet the following criteria:
1. Must have pathologically confirmed FL (Grade 1, 2, or 3A) or MZL.
2. Relapsed and/or refractory to >=2 prior lines of chemotherapy based on standard
of care that include at least 1 anti-CD20-based regimen, as well as alkylating
agents (example cyclophosphamide or bendamustine).
3. Participants must be ineligible for or refusal to hematopoietic stem cell
4. If the participants have relapsed or progressed after achieving a response
(defined as CR or PR), documented, investigator-assessed relapse or progression
after the last treatment is required.
3. Measurable disease per IWG 2007 criteria.
4. Eastern Cooperative Oncology Group performance status score of 0 or 1.
5. Life expectancy of longer than 3 months.
6. Adequate organ function, including the following:
1. Bone marrow reserve: absolute neutrophil count >=1,000 per cubic millimeter
(/mm^3), platelet count >=75,000/mm^3 (>=50,000/mm^3 for participants with bone
marrow involvement), and hemoglobin >=8 gram per deciliter (g/dL) (red blood cell
[RBC] and platelet transfusion allowed >=14 days before assessment).
2. Hepatic function: total bilirubin less than or equal to (<=) 1.5*the upper limit
of the normal range (ULN); alanine aminotransferase and aspartate
3. Renal function: creatinine clearance >=60 milliliter per minute (mL/min) either
as estimated by the Cockcroft-Gault equation.
1. Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases as
indicated by positive cytology from lumbar puncture or computed tomography
(CT)/magnetic resonance imaging (MRI) by local assessment.
2. Systemic anticancer treatment (including investigational agents) less than 3 weeks
before the first dose of study treatment (<=4 weeks for antibody-based therapy
including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell
engager agent; <=8 weeks for cell-based therapy or anti-tumor vaccine).
3. Radiotherapy less than (<) 3 weeks before the first dose of study treatment. If prior
radiotherapy occurred <4 to 6 weeks before the study start, as radiated lesions cannot
be reliably assessed by fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography
(PET), nonradiated target lesions are required for eligibility.
4. Prior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time
without full hematopoietic recovery before Cycle 1 Day 1, or allogeneic stem cell
transplant at any time.
5. Any clinically significant comorbidities, such as uncontrolled pulmonary disease
(example, severe chronic obstructive pulmonary disease with hypoxemia, interstitial
lung disease, radiation induced lung injury), known impaired cardiac function or
clinically significant cardiac disease, active CNS disease, or any other condition
that could, in the opinion of the investigator, compromise the participant's safety
and participation in the study per protocol.
6. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
absorption or tolerance of TAK-659.
7. Use or consumption of any of the following substances:
Received medications, supplements, or food/beverages that are P-glycoprotein (P-gp)
inhibitors or inducers or strong cytochrome P450 (CYP) 3A inhibitors or inducers within a
certain time frame prior to the first dose of study drug. Depending on the substance, the
washout period for P-gp inhibitors or inducers or strong CYP3A inhibitors or inducers will
be either 7 days or 5 times the half-life (half-life is related to the time required for
elimination from the body). The washout period for grapefruit containing food or beverages
is 5 days.